US FDA proposes higher bar for accelerated approvals for cancer drugs
Send a link to a friend
[March 25, 2023]
(Reuters) -The U.S. health regulator on Friday proposed cancer
drug developers in most cases conduct more rigorous trials to seek
accelerated approval for their candidates.
The Food and Drug Administration's proposed recommendation follows
criticism for the accelerated approval pathway, as well as an
independent federal review into it after the controversial nod for
Biogen Inc's Alzheimer's treatment Aduhelm.
Accelerated approvals allow the agency to move therapies that target
serious and life-threatening conditions to the market more quickly but
have been criticized because some drugs have later been proven to be
ineffective.
The FDA proposed that companies conduct randomized controlled trials in
which patients receive either a therapy or another alternate treatment
instead of trials that test the drug without a comparator, known as
single-arm studies.
Single-arm studies can be conducted in some cases, but those need to be
discussed with the agency beforehand, it said.
"Given the limitations of single-arm trials, a randomized controlled
trial is the preferred approach to support an application for
accelerated approval," the FDA said.
[to top of second column]
|
Sign is seen outside of the Food and
Drug Administration (FDA) headquarters in White Oak, Maryland, U.S.,
August 29, 2020. REUTERS/Andrew Kelly
Drug developers who submit
"single-arm" studies to gain accelerated approval typically conduct
a separate trial after the approval to confirm clinical benefits.
The regulator suggested two approaches - one of conducting a
randomized clinical trial before getting the accelerated nod and
then again to confirm the benefits, and another of holding just one
trial to seek the nod with long-term follow-up.
Running one long randomized trial has the advantage of providing
quicker verification of the benefits, the FDA said.
In the past few years, Merck & Co Inc's Keytruda's authorization as
a treatment for certain lung cancer patients was pulled back and TG
Therapeutics Inc's lymphoma drug was withdrawn. Those accelerated
approvals were based on single-arm studies.
(Reporting by Leroy Leo in Bengaluru; Editing by Maju Samuel, Sriraj
Kalluvila and Richard Chang)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |